Premium
A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R) SYSTEMIC ANAPLASTIC LARGE‐CELL LYMPHOMA (SALCL) OR R/R HODGKIN LYMPHOMA (HL)
Author(s) -
Locatelli F.,
MauzKoerholz C.,
Neville K.,
Llort A.,
Beishuizen A.,
Daw S.,
Pillon M.,
Aladjidi N.,
Klingebiel T.,
LandmanParker J.,
MedinaSanson A.,
August K.,
Huebner D.,
Sachs J.,
Hoffman K.,
Kinley J.,
Song S.,
Song G.,
Zhang S.,
Gore L.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_111
Subject(s) - medicine , brentuximab vedotin , refractory (planetary science) , anaplastic large cell lymphoma , lymphoma , gastroenterology , adverse effect , dosing , oncology , surgery , hodgkin lymphoma , astrobiology , physics